Journal Information
Vol. 33. Issue 5.
Pages 609-614 (May 2009)
Vol. 33. Issue 5.
Pages 609-614 (May 2009)
Nuevas terapias de diana celular: indicaciones, resultados ytolerabilidad
Visits
2795
This item has received
Article information
Los avances en la comprensión de la biologíamolecular del RCC ha dado lugar al desarrollo detratamientos biológicos dirigidos (terapias diana)que representan, por vez primera en más de quinceaños de tan solo disponer de las citocinas comoarma terapéutica, un avance significativo en el tratamientode esta enfermedad, con una mejoraimportante en la supervivencia libre de enfermedady con algunos fármacos, de la supervivencia global.Asimismo, el perfil de toxicidad con respecto a lostratamientos considerados estándar como las citoquinashan mejorado de forma ostensible.
Palabras clave:
Cáncer renal metastásico, Terapia diana celular, Sunitinib, Sorafenib,Temsirolimus, Overolimus
Advances in understanding of the molecular biology of RCC have led to development of targeted biological treatments (targeted therapies) which, after more than 15 years in which the only therapeutic weapons available were cytokines, represent a significant advance in the treatment of this disease, resulting in a significant improvement in disease-free survival and, with some drugs, in overall survival. The toxicity profile has also markedly improved as compared to standard treatments such as cytokines.
Keywords:
Metastatic renal cancer
Cell targeted therapy
Sunitinib
Sorafenib
Temsirolimus
Overolimus
These are the options to access the full texts of the publication Actas Urológicas Españolas
Subscriber
Subscribe
Purchase
Contact
Phone for subscriptions and reporting of errors
From Monday to Friday from 9 a.m. to 6 p.m. (GMT + 1) except for the months of July and August which will be from 9 a.m. to 3 p.m.
Calls from Spain
932 415 960
Calls from outside Spain
+34 932 415 960
E-mail